Table 5 The representative completed clinical trials about osteosarcoma
From: A 10-year bibliometric analysis of osteosarcoma and cure from 2010 to 2019
No. | Study Title | Conditions | Interventions |
|---|---|---|---|
1 | Investigation of [6R] 5,10-methylenetetrahydrofolate as Rescue Therapy for Osteosarcoma Patients Treated with HDMTX | Osteosarcoma | Drug: Calcium Folinate and [6R] 5,10-methylenetetrahydrofolate |
2 | Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma | Osteosarcoma | Drug: Cisplatin, Doxorubicin and Methotrexate |
3 | Glembatumumab Vedotin in Treating Patients with Recurrent or Refractory Osteosarcoma | Recurrent Osteosarcoma | Drug: Glembatumumab Vedotin Other: Laboratory Biomarker Analysis And Pharmacological Study |
4 | Eribulin Mesylate in Treating Patients with Recurrent or Refractory Osteosarcoma | Recurrent Osteosarcoma | Drug: Eribulin Mesylate Other: Pharmacological Study |
5 | Chemotherapy for Patients with Osteosarcoma | Osteosarcoma | Drug: Pemetrexed |
6 | Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung | Osteosarcoma Metastatic | Drug: Cisplatin liposomal |
7 | Preventing Nephrotoxicity and Ototoxicity from Osteosarcoma Therapy | Osteosarcoma | Drug: Pantoprazole and High-dose methotrexate infusion duration |
8 | Inhaled Sargramostim in Treating Patients with First Pulmonary (Lung) Recurrence of Osteosarcoma | Metastatic Cancer Sarcoma | Biological: sargramostim Procedure: conventional surgery |
9 | Differentiation of Bone Sarcomas and Osteomyelitis with Ferumoxytol-Enhanced MRI | Bone Cancer Osteosarcoma | Drug: Feraheme Procedure: Magnetic Resonance Imaging (MRI) scan |
10 | Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma | Sarcoma | Drug: Dacarbazine |
11 | A Study of Bevacizumab in Combination with Chemotherapy for Treatment of Osteosarcoma | Osteosarcoma | Biological: Bevacizumab Drug: Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, etoposide Procedure: Surgery Radiation: Radiotherapy |
12 | A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma | Osteosarcoma | Drug: Cyclophosphamide and Sirolimus |
13 | Samarium Sm 153 and Stem Cell Transplant Followed by Radiation Therapy Patients with Osteosarcoma | Sarcoma | Biological: filgrastim Drug: ifosfamide Procedure: peripheral blood stem cell transplantation Radiation: Sm-EDTMP (low dose) and Sm-EDTMP (higher dose) |
14 | Gemcitabine and Docetaxel in Treating Patients with Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing’s Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma | Sarcoma | Biological: filgrastim and pegfilgrastim Drug: docetaxel and gemcitabine hydrochloride Genetic: microarray analysis Other: laboratory biomarker analysis and pharmacokinetic study |
15 | Temsirolimus and Cixutumumab in Treating Patients with Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma Metastatic Osteosarcoma | Recurrent Osteosarcoma | Biological: Cixutumumab Other: Laboratory Biomarker Analysis Drug: Temsirolimus |
16 | Therapeutic Angiotensin-(1–7) in Treating Patients with Metastatic Sarcoma That Cannot Be Removed by Surgery | Bone Cancer Metastatic Osteosarcoma | Drug: therapeutic angiotensin-(1–7) Other: laboratory biomarker analysis |
17 | Sorafenib in Treating Patients with Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) | Metastatic Osteosarcoma Recurrent Osteosarcoma | Drug: sorafenib tosylate Procedure: therapeutic conventional surgery, computed tomography and dynamic contrast-enhanced magnetic resonance imaging Other: laboratory biomarker analysis and pharmacological study |
18 | Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients with Recurrent Sarcoma | Sarcoma | Drug: temsirolimus plus liposomal doxorubicin |
19 | A Study of Pemetrexed in Children with Recurrent Cancer | Osteosarcoma | Drug: pemetrexed |
20 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients with Advanced or Metastatic Sarcoma Metastatic Osteosarcoma | Recurrent Osteosarcoma | Drug: Gamma-Secretase Inhibitor RO4929097 and Vismodegib Other: Laboratory Biomarker Analysis and Pharmacological Study |
21 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients with Recurrent/ Refractory Solid Tumors | Osteogenic Sarcoma | Drug: nab-paclitaxel |
22 | Cixutumumab and Temsirolimus in Treating Younger Patients with Recurrent or Refractory Sarcoma | Recurrent Osteosarcoma | Biological: Cixutumumab Other: Laboratory Biomarker Analysis Drug: Temsirolimus |
23 | Cixutumumab in Treating Patients with Relapsed or Refractory Solid Tumors | Recurrent Osteosarcoma | Biological: cixutumumab Other: laboratory biomarker analysis |
24 | Alisertib in Treating Young Patients with Recurrent or Refractory Solid Tumors or Leukemia | Recurrent Osteosarcoma | Drug: Alisertib Other: Laboratory Biomarker Analysis and Pharmacological Study |
25 | Depsipeptide (Romidepsin) in Treating Patients with Metastatic or Unresectable Soft Tissue Sarcoma | Adult Extraskeletal Osteosarcoma | Drug: romidepsin |
26 | Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma | Relapsed Ewing Sarcoma Refractory Ewing Sarcoma | Drug: Linsitinib |
27 | Olaparib in Adults with Recurrent/Metastatic Ewing’s Sarcoma | Ewing’s Sarcoma | Drug: Olaparib |
28 | Cytarabine in Treating Young Patients with Recurrent or Refractory Ewing’s Sarcoma | Sarcoma | Drug: cytarabine |
29 | Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients with Newly-Diagnosed Metastatic Ewing’s Sarcoma Family of Tumors | Sarcoma | Drug: celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, MESNA and Filgrastim Procedure: conventional surgery Radiation: radiation therapy |
30 | Sunitinib in Treating Patients with Metastatic, Locally Advanced, or Locally Recurrent Sarcomas | Sarcoma | Drug: sunitinib malate |
31 | Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide with or Without Bevacizumab in Treating Young Patients with Refractory or First Recurrent Extracranial Ewing Sarcoma | Ewing Sarcoma of Bone | Drug: topotecan hydrochloride, vincristine sulfate and cyclophosphamide Biological: bevacizumab |
32 | Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients with Relapsed/Refractory Ewing’s Sarcoma and Neuroblastoma | Neuroblastoma Sarcoma | Drug: Cyclophosphamide, Topotecan, and Bevacizumab |
33 | A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Ewing’s | Sarcoma | Biological: IMC-A12 (cixutumumab) |
34 | Trial of Dasatinib in Advanced Sarcomas | Sarcoma, Ewing’s | Drug: Dasatinib |
35 | Trabectedin in Treating Young Patients with Recurrent or Refractory Soft Tissue Sarcoma or Ewing’s Family of Tumors | Recurrent Ewing Sarcoma | Drug: trabectedin Other: pharmacological study |
36 | A Pilot Study of Autologous T-Cell Transplantation with Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas | Ewing’s Sarcoma Rhabdomyosarcoma | Biological: therapeutic autologous dendritic cells Drug: indinavir sulfate Procedure: peripheral blood stem cell transplantation |
37 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients with Sarcoma | Sarcoma | Biological: filgrastim Drug: cisplatin, doxorubicin hydrochloride, ifosfamide and melphalan Procedure: peripheral blood stem cell transplantation |
38 | Study Of CP-751,871 In Patients with Ewing’s Sarcoma Family of Tumors | Ewing’s Sarcoma | Drug: CP-751,871 |
39 | Arsenic Trioxide in Treating Patients with Advanced Neuroblastoma or Other Childhood Solid Tumors | Sarcoma | Drug: arsenic trioxide |
40 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed High Grade Glioma | Adult Medulloblastoma | Radiation: radiation therapy Drug: temozolomide and plerixafor Other: laboratory biomarker analysis and pharmacological study |
41 | Therapy to Treat Ewing’s Sarcoma, Rhabdomyosarcoma or Neuroblastoma | Sarcoma | Drug: Tumor Purged/CD25 Depleted Lymphocytes and rhIL-7 Biological: Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine and Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine |